O ne of the most common and important interventions in providing care for critically ill children is the alleviation of pain and anxiety. The selection and method of administering sedative and analgesic medications to accomplish this goal is highly variable. Historically it has been based on individual physician preference and subjective nursing assessment of pain and anxiety. Infusions of analgesic and sedative agents are frequently used in intensive care units (ICUs) as a means to provide a continuous level of comfort to critically ill patients (1, 2) . This approach has been proven to decrease the discomfort associated with mechanical ventilation (MV), traumatic and surgical wounds, invasive devices, and procedures. In addition, analgesics and sedatives decrease oxygen consumption, modulate the intensity of the stress response, foster patient safety in a potentially dangerous ICU environment (by reducing risks of agitation-related injury and dislodgement of critical invasive devices), and facilitate bedside nursing care (2) (3) (4) (5) .
Despite these benefits, continuous infusions of analgesics and sedatives have been identified as independent predictors of longer duration of MV as well as extended ICU and hospital length of stay (LOS) (6, 7) . Prolonged sedation has been associated with increased procedures, acquired neuromuscular disorders, delirium, and posttraumatic stress disorder (8) . Lastly, the long-term consequences of analgesics and sedatives on the developing brains of children are incompletely understood. Of particular concern, anesthetic drugs that alter synaptic transmission at ␥-aminobutyrate type A and/or N-methyl-D-aspartate glutamate receptors cause neuroapoptosis in the developing brain and subsequent neurocognitive impairment in neonatal animal models (9) (10) (11) .
There is growing evidence that a sedation protocol for mechanically ventilated patients may decrease morbidity, LOS, and time on MV for critical care patients. Although there are published guidelines and many protocol examples for adult patients in the literature (8, (12) (13) (14) , there is a paucity of practical evidence for children (15, 16) . Adapting published adult protocols for pediatric patients is challenging, and the safety and efficacy of a sedation and weaning protocol in children is unknown, although it is currently being studied in a multi-institutional randomized, controlled trial (The Randomized Evaluation of Sedation Titration for Respiratory Failure [RESTORE] study, NCT00814099; http://clinicaltrials.gov). With a strategy Objective: To evaluate the effect of a nursing-driven sedation protocol for mechanically ventilated pediatric patients on duration of use of analgesic and sedative medications. We hypothesized that a protocol would decrease length of sedation use and decrease days of mechanical ventilation and length of stay.
Design: Retrospective cohort study with historical controls. Setting: Thirty-one-bed tertiary care, medical-surgical-cardiac pediatric intensive care unit in a metropolitan university-affiliated children's hospital.
Patients: Children requiring mechanical ventilation longer than 48 hrs not meeting exclusion criteria.
Interventions: Before protocol implementation, sedation was managed per individual physician orders. During the intervention period, analgesia and sedation were managed by nurses following an algorithm-based sedation protocol based on a comfort score.
Measurements and Main Results:
The observation group included consecutive patients admitted during the 12-month period before protocol education and implementation (n ‫؍‬ 153). The intervention group included patients admitted during the 12 months following protocol implementation (n ‫؍‬ 166). The median duration of total sedation days (intravenous plus enteral) was 7 days for the observation period and 5 days for the intervention period (p ‫؍‬ .026). Specifically, the median duration of morphine infusion was 6 days for the observation period and 5 days for the intervention period (p ‫؍‬ .015), whereas the median duration of lorazepam infusion was 2 days for the observation period and 0 days for the intervention period. After adjusting for severity of illness with the pediatric risk of mortality III (PRISM III) score, the Cox proportional hazards regression analysis demonstrated that at any point in time, patients in the intervention group were 23% more likely to be off all sedation (heart rate 0.77, p ‫؍‬ .020). Additionally, the intervention group tended to be associated with fewer days of mechanical ventilation (heart rate 0.81, p ‫؍‬ .060) and decreased pediatric intensive care unit length of stay (heart rate 0.81, p ‫؍‬ .058), although these associations did not quite reach statistical significance.
Conclusion: A pediatric sedation protocol can significantly decrease days of benzodiazepine and opiate administration, which may improve pediatric intensive care unit resource utilization. (Crit Care Med 2011; 39:683-688) KEY WORDS: sedation protocol; pediatric sedation; continuous process improvement; morphine; lorazepam; opiates; benzodiazepines supported by continuous process improvement principles and Lean methodology in use at our institution (17) , our multidisciplinary research team sought to design a pediatric sedation protocol that would be safe and effective and could be rapidly implemented in our large pediatric ICU (PICU). Our hypothesis was that a nursing-driven pediatric sedation protocol would decrease exposure to analgesics and sedatives, decrease ICU LOS, and decrease days of MV.
METHODS
Protocol Development. A multidisciplinary team that included PICU physicians, nurses, and a pharmacist met regularly over a period of 6 months to develop the Seattle Children's Comfort Protocol (SCCP) (Fig. 1) . The team extensively reviewed published literature, order sets and protocols available from other institutions, and recommendations from individual experts in the field, such as Seattle Children's Hospital Pain Service physicians. Consensus was reached by all members of the team to continue with accepted institution preference for morphine and lorazepam due to staff comfort, experience, and clinical success with these medications. We did not reach team consensus on inclusion of a daily interruption of sedation in the initial protocol, which is often found in adult protocols (18, 19) , and as such it was not included. Concerns included timing of the interruption, variability of awakening time, ability to provide 1:1 nursing to closely watch each patient during awakening, safety and risk of self-extubation, and variable pediatric developmental level as related to ability to understand verbal commands and calming.
It was agreed that one protocol based on a comfort score would be developed in contrast to many adult protocols that separate pain and anxiety. To maximize compliance and facilitate education, we decided to continue with use of our institution's comfort scoring system, the Seattle PICU Comfort Score (Fig. 2) , although there are other nationally recognized and validated comfort scores available for pediatrics (20, 21) . A specific goal comfort score is ordered on morning interdisciplinary rounds depending on the depth of sedation preferred for an individual patient. For most patients, a score of "2" is typically appropriate, although as they near extubation, this order may be adjusted to a "3."
Once the protocol was finalized, all staff completed 1 hr of required small group training that included a pharmacology review and direction on the use of the order set and SCCP. During the first week of implementation, a nurse educator was assigned to work individually with each bedside nurse to answer questions and ensure the SCCP was being properly implemented. Pharmacy staff took responsibility for daily auditing of protocol adherence, order accuracy, and reviewing compliance with titration instructions.
Study Design and Data Collection. Early in the protocol development process, the team decided to objectively review the impact of the sedation protocol on the clinical care of our patient population. This research was conducted at Seattle Children's Hospital, a university-affiliated metropolitan children's hos- 
YES
Decrease drip by 5 mcg/kg/hr.
Continue boluses prn. If on lorazepam infusion, decrease this first -may also decrease both at the same time.
NO
Discuss with MD. Consider increasing max dose or using alternative medications (Fentanyl, Dilaudid, Dexmedetomidine). Continue increasing drip every time 3 boluses are required in 4 hour time period.
Reassess at 0400 and 1600. Maintaining goal comfort score?
If > 4 lorazepam boluses in 12 hr period, may notify MD to order lorazepam drip to start at 10 mcg/kg/hr. Increase by 5 mcg/kg/hr immediately after 3rd bolus given in 6 hour period. Decrease by 5 mcg/kg/hr at 0400 and 1600 if no boluses given.
Consider increasing goal comfort score. Ask MD to order "PICU Extubation Orderset" AND "PICU Opioid and Benzodiazepine Weaning Orderset". Ask MD to decrease morphine and lorazepam prn doses by half and space to q2 and q4 prn respectively.
YES
Continue current infusion rate. Bolus morphine 0.1 mg/kg q15 min prn to goal comfort score (MAX 4mg). During the observation period, patients were managed by using independent physician-directed approaches requiring specific physician's orders for sedation selection, dosing, and titration. During the intervention period (following healthcare staff education and training), children admitted to the ICU already intubated or who required intubation during admission were placed on the SCCP, although only those patients requiring MV for longer than 2 days were included in our retrospective review.
Medical record numbers for patients meeting inclusion criteria were obtained from the virtual PICU system (vPICU, http://www.vpicu.org) for both the observation period (January 1 to December 31, 2007) and intervention period (May 1, 2008 to April 30, 2009). Data abstracted from electronic charts included inclusion and exclusion criteria, age, sex, diagnosis, Pediatric Risk of Mortality III (PRISM III) score (22) , LOS, duration of MV, IV sedation including medication and duration, enteral sedation including medication and duration, and whether or not the patient had undergone surgery. Total days of sedation (reported in tables as IV plus enteral) included the IV infusions received during hospitalization in addition to any oral benzodiazepines or opiates given on a scheduled basis while admitted or prescribed at discharge. Outpatient medications were tracked with our electronic records system for refills, and outpatient physician notes were reviewed to determine exact length of time required for weaning medications (typically oral morphine, methadone, or lorazepam). There were only a small number of patients who required outpatient weaning, and all of these records were available for review to confirm date of cessation of weaning medication (most followed by the cardiac, transplant, or oncology services). During the intervention period, we also reviewed charts for physician orders for the SCCP and noted any reasons for protocol noncompliance.
Statistical Analysis. Baseline patient characteristics of the two study groups were compared by using descriptive statistics. We observed a non-normal distribution of the study patient outcome measures (total sedation days, duration of MV, and LOS) when the data were plotted as histograms. Outcome measures were reported as both mean and median values with respective standard deviations and interquartile ranges. Wilcoxon's rank sum test was used to compare continuous nonparametric outcome measures between groups. Similarly, given the non-normal distribution of the data, a Cox proportional hazards regression analysis was performed to assess the differences between the intervention group and the traditional group after adjustment for pediatric severity of illness (using a PRISM III score). The hazard ratio represents the likelihood at any point in time that a child in the intervention group (as compared with the observation group) would be on a given therapy. All statistical tests were two-sided. Data were analyzed by using STATA 10 (Stata, College Station, TX).
RESULTS
Patients. Two hundred eighty-five patients met inclusion criteria during the observation period. After exclusions were made, 153 patient charts were analyzed (Fig. 3) . The records of 325 consecutive patients meeting inclusion criteria during the intervention period were reviewed, and data from 166 patients were ultimately analyzed after review for exclusion criteria. The demographics of both groups were similar (Table 1) as were reasons for study exclusion. There were 30 patients in the intervention group that would have met criteria to be placed on the SCCP but were excluded by the ordering physician due to preference for alternative narcotic, concerns for profound hypotension or heart failure, reintubation or readmission before previous narcotic weans, parent refusal, or morphine allergy. Median PRISM III score for these patients was comparable with study populations at 6.5. Of note, more than half of all exclusions took place in the first 4 months of protocol introduction with the remainder in the following 8 months as staff became more comfortable with use of the SCCP.
Outcomes. The duration of sedation exposure, duration of MV, and PICU LOS were compared by study group (Table 2) . Patients in the intervention group were exposed to significantly fewer days of morphine infusion, lorazepam infusion, and total sedation (IV plus enteral) than patients in the observation group. For the primary outcome, the intervention group (as compared with the observation group) was 23% more likely to be off all sedation (heart rate 0.77, 95% confidence interval: 0.61-0.96, p ϭ .020). For secondary analyses, the intervention group tended to be associated with fewer days of MV (heart rate 0.81, p ϭ.060) and PICU LOS (heart rate 0.81, p ϭ .058), although these associations did not quite reach statistical significance ( Table 3) .
The rate of unplanned extubations during each study period was also retrospectively reviewed and summarized. (http://mmp-bench.com) during these time periods was 0.65 accidental extubations per 100 days. These data include all ventilated patients admitted to our ICU, including those patients meeting criteria for this study. Lastly, we collected data on dexmedetomidine use during our study period. Dexmedetomidine was used in 74 of 153 patients (48%) in the observation group and only 40 of 166 patients (25%) in the intervention group during some point in the course of their ICU therapy. We found a strong association between dexmedetomidine use (yes/no) and total sedation days (median) in the observation group (dexmedetomidine yes: 12 days vs. dexmedetomidine no: 6 days, p ϭ .018). We found no association between dexmedetomidine use and total sedation days in the intervention group (dexmedetomidine yes: 5 days vs. dexmedetomidine no: 5 days, p ϭ .244).
DISCUSSION
Implementation of a nursing-driven pediatric sedation protocol significantly decreased the duration of both opiate and benzodiazepine continuous infusions as well as total duration of sedative exposure. As found in previous adult studies, a multidisciplinary team approach was successfully used to create a sedation protocol that empowers intensive care nurses to safely administer and titrate continuous infusions of opiates and benzodiazepines for critically ill children. When we accounted for the potential confounding effect of severity of illness as measured by PRISM III score, our data suggest that a pediatric sedation protocol very likely can also decrease duration of MV and ICU LOS. Importantly, we found no increase in the rate of unplanned extubations. We found that dexmedetomidine use fell by approximately 50% in our study population, suggesting that children required fewer alternative sedation therapies while on the SCCP; however, this would need future study to verify. We also found no association between dexmedetomidine use and total sedation days (our primary outcome measure) in patients on the SCCP.
The positive changes seen in our unit are likely a result of many factors: Implementation of a nursing-driven protocol, education of the healthcare team with respect to the medications used for pain and sedation, and a growing awareness of the importance of reducing unnecessary sedation. This is a single center study in a teaching hospital; our protocol may not be easily translatable to other PICUs. The SCCP was designed to meet the needs of our unit and was created with input from our nursing staff and from specialists utilizing our services. Similar centers will likely need to construct individual protocols to meet their own needs.
We encountered many challenges in developing our protocol. In reviewing published protocols, we found that many centers use different medication algorithms for pain and anxiety. As discrimination of pain and anxiety in children is difficult, we instead decided to focus on a single "comfort" protocol to address both variables with titration guided by a comfort scale. The Seattle PICU Comfort Tool was developed at our institution, has been in use in the ICU for approximately 10 yrs, and thus was well known to staff. Although this tool is not a nationally validated scoring system, it was derived from the adult Ramsay sedation tool (23) and developed as part of a quality improvement project with inter-rater reliability testing completed before use. An- b total sedation days are defined as total days of sedative medications, including all routes (intravenous and enteral) as well as all locations (in the intensive care unit, the pediatric ward, and home). other challenge in developing the SCCP was to standardize sedation provided to both our medical and surgical patients with a single algorithm in an effort to decrease risk of error given that nurses may work in both the medical/surgical and cardiac ICUs. After much collaborative discussion, we chose to utilize morphine as the primary sedation agent for all patients on the protocol. The Seattle Children's team of anesthesiologists, intensivists, and pharmacists collaboratively adopted the use of morphine years ago due to its analgesic and sedative properties, its pediatric safety and efficacy profile, relatively slow development of tachyphylaxis, and its cost-effectiveness. Common concerns regarding histamine release with morphine has been shown to be less problematic with infusions (24, 25) . Use of morphine and lorazepam for longterm sedation has also been supported by recent consensus guidelines (8) .
Particularly when dosing is high, weaning of long-term sedation can require days to months, and this may prolong duration of MV and hospitalization (26) . Children may be sent home on oral analgesic/ sedative medications and weaning protocols that create risk for patient and family safety concerns. A key component of the SCCP is a rapid attainment of comfort with bolus dosing and titration of the infusion, but with subsequent mandatory assessment every 4 hrs and reduction of the infusion recommended every 12 hrs once the patient is comfortable. In this way, patients are slowly, but steadily, weaned from sedation before extubation.
Aside from minimizing sedation duration, we have also demonstrated how a pediatric ICU sedation protocol can decrease days of MV and ICU LOS, although our data in these regards did not quite reach statistical significance given the small nature of this single-center study. This decrease in utilization of scarce pediatric medical resources may impart a large cost savings to the patient, the hospital, and society. Further prospective study with large numbers of subjects utilizing pediatric tools for assessment of delirium and posttraumatic stress disorder along with long-term follow-up of neurodevelopmental effects is needed to fully answer such questions. From a hospital perspective, we hope to improve safe patient flow through the ICU, decrease costs related to sedation, decrease costs related to complications in the ICU or ward related to drug exposure, and improve staff satisfaction through use of standardization and guidelines (27, 28) .
Patient deaths during each time period were excluded in this study to further describe a change in the total days of sedation, MV, and LOS. Median PRISM III score for patients who expired in the observation group was 16.5 and for the intervention group was 11. Many of these patients required extracorporeal life support or a paralytic infusion thereby removing them from protocol inclusion. Many others were found to have fatal malignancies, failed bone marrow or solid organ transplants, or inoperable cardiac conditions. Deaths were reviewed by authors and circumstances found to be similar between groups. Although it is impossible to know without further review and alternative study design, there was no documentation discovered in these charts implicating the method of sedation as a contributing factor to death.
Limitations
We cannot generalize our results to the critically ill child with neurologic disease or the child who is so ill as to require extracorporeal life support or go on to die as those populations were excluded from our study. Specifically, another agent such as fentanyl may be preferable for patients who have severe hemodynamic compromise or who require frequent neurologic exams, and we did not test the efficacy of morphine in these populations. Our retrospective design and use of historical controls is another important limitation to our study as practice and patient populations may change over time. A retrospective design was deemed necessary as the research team felt that attempting to train only half of our entire healthcare team in an effort to randomize to different arms of a study would not be feasible in our unit and would lead to contamination of results during the intervention phase. Unfortunately, our retrospective electronic chart review was also not adequate to capture total milligrams of sedatives and narcotics administered daily. It is possible that even though the total days of sedative administration decreased, the actual amount (in milligrams) of these medications may have increased as has been reported by other investigators using similar protocols (19) . Total amount of drug exposure (in milligrams), incidence of withdrawal symptoms and delirium (29) , and number of children requiring weaning regimens following discharge from the ICU should be studied in a prospective fashion.
CONCLUSION
The development and implementation of a pediatric comfort protocol that addresses analgesia and sedation is feasible and safe. Initiation of this quality improvement protocol significantly decreased exposure of critically ill children to analgesic and sedative medications with an associated reduction in days of MV and ICU LOS. The key components of this protocol include the use of a consistent comfort metric, nursing education and empowerment, and forced, scheduled assessments with defined responses.
